FDA lifts partial hold on Icagen drug

The FDA has lifted a partial clinical hold on Icagen's photosensitive epilepsy drug ICA-105665. The agency had placed the hold on the drug back in March as a result of some preclinical data. Icagen is now planning proof-of-concept trials of the drug for both epipelpsy and pain. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.